IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis.

Clicks: 321
ID: 100383
2019
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
IL-17 has been implicated in the pathogenesis of multiple sclerosis (MS). Here, we show that blockade of IL-17A, but not IL-17F, attenuated experimental autoimmune encephalomyelitis (EAE). We further show that IL-17A levels were elevated in the CSF of relapsing-remitting MS (RRMS) patients and that they correlated with the CSF/serum albumin quotient (Qalb), a measure of blood-brain barrier (BBB) dysfunction. We then demonstrated that the combination of IL-17A and IL-6 reduced the expression of tight junction (TJ)-associated genes and disrupted monolayer integrity in the BBB cell line hCMEC/D3. However, unlike IL-17A, IL-6 in the CSF from RRMS patients did not correlate with Qalb. These data highlight the potential importance of targeting IL-17A in preserving BBB integrity in RRMS.
Reference Key
setiadi2019il17ajournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Setiadi, A Francesca;Abbas, Alexander R;Jeet, Surinder;Wong, Kit;Bischof, Antje;Peng, Ivan;Lee, James;Bremer, Meire;Eggers, Erica L;DeVoss, Jason;Staton, Tracy;Herman, Ann;von Büdingen, H-Christian;Townsend, Michael J;
Journal journal of neuroimmunology
Year 2019
DOI
S0165-5728(18)30579-4
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.